Psychiatr. praxi 2017; 18(3) [Klin Farmakol Farm. 2017;31(3):10-15]

Long-acting injectable antipsychotics in clinical practice

MUDr. Bc. Libor Ustohal, Ph.D.
Psychiatrická klinika LF MU a FN Brno
CEITEC MU, Brno

The article summarizes basic data concerning long-acting injectable or depot antipsychotics, which are currently available in theCzech Republic. They include four first generation antipsychotics (fluphenazine, flupenthixol, haloperidol and zucklopenthixol)and four second generation antipsychotics (aripiprazole, olanzapine, risperidone and paliperidone). It focuses especially on thetreatment initiation and dosage regimen. Basic advantages and disadvantages of depot formulation are discussed as well as itsefficacy in the prevention of relapse and the risk of adverse-events compared to oral formulation of antipsychotics.

Keywords: depot antipsychotics, LAI, schizophrenia, fluphenazine, flupenthixol, haloperidol, zucklopenthixol, risperidone, paliperidone,
olanzapine, aripiprazole

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ustohal L. Long-acting injectable antipsychotics in clinical practice. Psychiatr. praxi. 2017;18(3):.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Afluditen, Souhrn údajů o přípravku, 2016.
    2. Meyer JM. Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectrums 2013; 18: 58-68. Go to original source... Go to PubMed...
    3. Fluanxol Depot, Souhrn údajů o přípravku, 2015.
    4. Ustohal L, Ustohal L. Přírůstek hmotnosti, obezita a schizofrenie. Čes a slov Psychiat 2017; 113(1): 26-31.
    5. Haloperidol Decanoat-Richter, Souhrn údajů o přípravku, 2013.
    6. Cisordinol Depot, Souhrn údajů o přípravku, 2015.
    7. Risperdal Consta, Souhrn údajů o přípravku, 2015.
    8. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Halanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962. Go to original source...
    9. Xeplion, Souhrn údajů o přípravku, 2016.
    10. Trevicta, Souhrn údajů o přípravku, 2016.
    11. Zypadhera, Souhrn údajů o přípravku, 2016.
    12. Bushe CJ, Falk D, Anand E, Casillas M, Perrin E, Chhabra-Khanna R, Detke HC. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice. BMC Psychiatry 2015; 15: 65. Go to original source...
    13. Miyamoto S, Fleischhacker WW. The use of long-acting injectable antipsychotics in schizophrenia. Curr Treat Options Psych 2017; 4: 117-126. Go to original source... Go to PubMed...
    14. Abilify Maintena, Souhrn údajů o přípravku, 2016.
    15. Češková E, Vrzalová M. Optimalizace farmakoterapie schizofrenní poruchy. Psychiatr praxi 2012; 13(4): 156-159.
    16. Šilhán P, Kacířová I, Hýža M, Uřinovská R, Češková E, Grundmann M. Terapeutické monitorování hladin léčiv v psychiatrii - možnosti a využití v praxi. Psychiatr praxi 2016; 17(1): 10-14. Go to original source...
    17. Mayerová M, Turjap M, Ustohal L, Pivnička J, Češková E. Terapeutické monitorování plazmatických koncentrací olanzapinu a klozapinu. Čes a slov Psychiatr 2016; 112(4): 177-187.
    18. Češková E. Postoje psychiatrů k depotní léčbě. Psychiatr praxi 2013; 14(3): 102-104.
    19. Weiden PJ, Roma RS, Velligan DI, Alphs L, DiChiara M, Davidson B. The challenge of offering long-acting antipsychotic therapies: A preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry 2015; 76(6): 684-690. Go to original source... Go to PubMed...
    20. Verdoux H, Pambrun E, Tournier M, Bezin J, Pariente A. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study. Acta Psychiatr Scand 2017; 135: 429-438. Go to original source... Go to PubMed...
    21. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia - A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127: 83-92. Go to original source... Go to PubMed...
    22. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophr Bull 2014; 40(1): 192-213. Go to original source... Go to PubMed...
    23. Fagiolini A, Rocca P, De Giorgi S, Spina E, Amodeo G, Amore M. Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. Psychiatry Res 2017; 247: 257-264. Go to original source...
    24. Přikryl R, Přikrylová Kučerová H. Jak číst výsledky klinických studií srovnávající dlouhodobě působící injekční a perorální antipsychotika v léčbě schizofrenie? Čes a slov Psychiat 2014; 110(5): 259-263.
    25. Ostuzzi G, Bighelli I, So R, Furukawa TA, Barbui C. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res 2017; 183: 10-21. Go to original source...
    26. Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. Psychiatry Res 2016; 246: 750-755. Go to original source...
    27. Češková E, Přikryl R, Pěč O. Schizofrenie u dospělých. In Raboch J, Uhlíková P, Kellerová P, Anders M, Šusta M (eds.). Doporučené postupy psychiatrické péče IV. Praha: Psychiatrická společnost ČLS JEP 2014; s. 44-51.
    28. Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res 2016; 176: 220-230. Go to original source...
    29. Kishi T, Matsunaga S, Iwata N. Mortality risk associated with long-acting injectable antipsychotics: A systematic review and meta-analysis of randomized controlled trials. Schizophr Bull 2016; 42(6): 1438-1445. Go to original source...
    30. Pietrini F, Spadafora M, Tatini L, Talamba GA, Andrisano C, Boncompagni G, Manetti M, Ricca V, Ballerini A. LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment. Eur Psychiatry 2016; 37: 35-42. Go to original source...
    31. Pečeňák J. Antipsychotiká. In Pečeňák J, Kořínková V (eds). Psychofarmakológia. Bratislava: Wolters Kluwer 2016; s. 249-357.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.